NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting

NewLink Genetics Corporation (NASDAQ:NLNK) announced that updated Phase 1 data evaluating indoximod …

NewLink Genetics Corporation (NASDAQ:NLNK) announced that updated Phase 1 data evaluating indoximod ...